2026-06-29T09:29:07Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/135862023-08-26T20:48:32Zcom_20.500.14352_14col_20.500.14352_15
Antileukotrienes Improve Naso-Ocular Symptoms and Biomarkers inPatients With NARES and Asthma
De Corso, Eugenio
Anzivino, Roberta
Galli, Jacopo
Baroni, Silvia
Di Nardo, Walter
De Vita, Carla
Salvati, Antonio
Autilio, Chiara
Settimi, Stefano
Mele, Dario
Paludetti, Gaetano
Mullol, Joaquin
577.1
616-056.3-085
616.248-085
NARES
asthma
antileukotrienes
montelukast
eosinophils
eotaxin
precision medicine
Alergología
Bioquímica (Biología)
Farmacología (Farmacia)
3207.01 Alergias
2302 Bioquímica
3209 Farmacología
Objective: The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).Methods: We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in mono-therapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinor-rhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction,difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. Thefollowing clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), TotalSymptom Score of Patient-Reported Outcomes (TSS-PROs), and a Composite Symptoms Score (CSS). Patients were classified asresponders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkersin nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin-1 and eotaxin-2.Results: Aft er tre atment, s ig nificant reductions were observed for all the symptom scores. Forty-two of 78 patients were con-sidered responders. A significant reduction of eosinophils in nasal mucosa and of levels of eotaxin-1 and eotaxin-2 in nasal lavagewere observed after treatment in responder patients. Patients with asthma had an increased probability to be responders.Conclusion: NARES patients may benefit from treatment with montelukast. In particular, the presence of concomitantasthma may be predictive of a greater efficacy.
Sección Deptal. de Bioquímica y Biología Molecular (Biológicas)
Fac. de Ciencias Biológicas
TRUE
pub
2023-06-17T13:28:48Z
2023-06-17T13:28:48Z
2019
journal article
https://hdl.handle.net/20.500.14352/13586
1531-4995
10.1002/lary.27576
eng
open access
application/pdf
Wiley